Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003729 | Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia | terminated | Phase 2 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 24, 2012 | clinicaltrials |
| NCT00039351 | Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 32 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 |
| Sep 24, 2012 |
| clinicaltrials |
| NCT00060385 | Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma | terminated | Phase 2 / Phase 3 | 3 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00079261 | Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00054665 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2012 | clinicaltrials |
| NCT00058747 | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ | terminated | Phase 2 | 40 | Agenus Inc.INDUSTRY | 2 | Sep 7, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01679860 | Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma(PTCL-06) | completed | Phase 2 | 92 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00219726 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00397800 | Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 12 | Technical University of MunichOTHER | 1 | Aug 28, 2012 | clinicaltrials |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 25 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | terminated | Phase 2 | 9 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00030186 | Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation | completed | Phase 2 | 37 | CephalonINDUSTRY | 0 | Aug 23, 2012 | clinicaltrials |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma | terminated | Phase 2 | — | CephalonINDUSTRY | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00003131 | CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00003673 | CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Aug 22, 2012 | clinicaltrials |
| NCT01665001 | Personalized Therapy of Precursor Lymphoid Neoplasms | unknown | Phase 2 | 200 | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, GliwiceOTHER | 1 | Aug 17, 2012 | clinicaltrials |
| NCT01665014 | Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma | unknown | Phase 2 | 50 | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, GliwiceOTHER | 1 | Aug 17, 2012 | clinicaltrials |
| NCT00240565 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 93 | GlaxoSmithKlineINDUSTRY | 1 | Aug 13, 2012 | clinicaltrials |
| NCT00038857 | Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00762632 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Technical University of MunichOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00002547 | Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 280 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00067808 | Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 128 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00071396 | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00088218 | Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | completed | Phase 2 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00267059 | Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00267085 | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00382590 | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00418951 | Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections | completed | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00453193 | Alemtuzumab and Pentostatin In T-cell Neoplasms | terminated | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00569660 | Ph II Study of Azacitidine in Myelofibrosis | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00810576 | Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01031498 | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01222195 | Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00359892 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma | completed | Phase 2 | 13 | Gemin XINDUSTRY | 1 | Aug 6, 2012 | clinicaltrials |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 3, 2012 | clinicaltrials |
| NCT00483067 | 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00772655 | Zevalin® First Line in Follicular Lymphoma | unknown | Phase 2 | 60 | Charite University, Berlin, GermanyOTHER | 0 | Aug 2, 2012 | clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00067639 | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Sep 24, 2012source: clinicaltrials